Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
October 03, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A...
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
September 22, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in...
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
September 06, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's...
Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
August 29, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor...
Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
August 11, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating...
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
August 04, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical...
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
August 01, 2022 05:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
July 18, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
June 09, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...